Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Raw Materials (2022 - 2025)

Arcutis Biotherapeutics (ARQT) has 4 years of Raw Materials data on record, last reported at $5.0 million in Q4 2025.

  • For Q4 2025, Raw Materials rose 17.37% year-over-year to $5.0 million; the TTM value through Dec 2025 reached $5.0 million, up 17.37%, while the annual FY2025 figure was $5.0 million, 17.37% up from the prior year.
  • Raw Materials reached $5.0 million in Q4 2025 per ARQT's latest filing, down from $6.1 million in the prior quarter.
  • Across five years, Raw Materials topped out at $11.2 million in Q3 2023 and bottomed at $3.5 million in Q3 2022.
  • Average Raw Materials over 4 years is $6.6 million, with a median of $6.3 million recorded in 2023.
  • Peak YoY movement for Raw Materials: skyrocketed 220.64% in 2023, then crashed 63.49% in 2024.
  • A 4-year view of Raw Materials shows it stood at $5.7 million in 2022, then surged by 75.84% to $10.0 million in 2023, then tumbled by 56.79% to $4.3 million in 2024, then grew by 17.37% to $5.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Raw Materials were $5.0 million in Q4 2025, $6.1 million in Q3 2025, and $6.7 million in Q2 2025.